Compare Gaming and Leisure Properties Inc. Common Stock (GLPI) vs Oruka Therapeutics Inc. Common Stock (ORKA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gaming and Leisure Properties Inc. Common Stock vs Oruka Therapeutics Inc. Common Stock — how do they compare? Gaming and Leisure Properties Inc. Common Stock trades at $38.13 (market cap $11.15B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Gaming and Leisure Properties Inc. Common Stock is far larger — about 2.2× Oruka Therapeutics Inc. Common Stock's market cap, and Gaming and Leisure Properties Inc. Common Stock pays a 8.56% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gaming and Leisure Properties Inc. Common Stock for 0 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| GLPI | ORKA | |
|---|---|---|
Market Cap | $11.15B | $5.18B |
Volume | 1,865,490 | 490,798 |
Sector | Real Estate | Health |
52-Week High | $49.82 | $113.08 |
52-Week Low | $37.59 | $26.19 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $19.21B | $4.31B |
Dividend Yield | 8.56% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gaming and Leisure Properties Inc. Common Stock
Gaming and Leisure Properties Inc. is a real estate investment trust that acquires, finances, and owns casino and gaming properties, which it leases to gaming operators under triple-net lease arrangements. It was the first publicly traded REIT focused on the gaming real estate sector in North America.
Read more on GLPI →About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →
